Advertisement

Digestive Diseases and Sciences

, Volume 58, Issue 5, pp 1403–1409 | Cite as

Hepatic Preservation Injury: Severity of Hepatitis C Recurrence and Survival After Liver Transplantation

  • Anthony J. Michaels
  • Renumathy Dhanasekaran
  • David P. Foley
  • Ahmad Alkhasawneh
  • Lisa Dixon
  • Consuelo Soldevila-Pico
  • Giuseppe Morelli
  • Roniel Cabrera
  • Virginia C. Clark
  • Roberto J. Firpi
Original Article
  • 180 Downloads

Abstract

Background

Preservation injury in the HCV liver transplant population has been reported to correlate with poorer survival outcomes compared to preservation injury in the non-HCV liver transplant population. However, determinants of progression to cirrhosis in HCV infection remain poorly defined in this population.

Aim

This study aimed to determine if the presence and severity of preservation injury impact the acceleration of HCV recurrence and survival after liver transplant.

Methods

We retrospectively reviewed liver transplant HCV patients over a 10-year period. Biopsies from postoperative day 7 were assessed for preservation injury and 4- and 12-month biopsies were assessed for fibrosis. Patients with Ishak fibrosis >0.8 Units/year were considered rapid fibrosers.

Results

Our study group consisted of 255 patients. The mean age was 49.3 years old, 180 (70.6 %) were male, and 221 (86.7 %) were Caucasian. The incidence of preservation injury on the 7-day biopsy was 69.0 %. A strong correlation between postoperative peak AST within the first week and preservation injury was found. The overall prevalence of rapid fibrosers at 4 months, 1 and 2 years was 47.4, 75.2, and 58.9 %, respectively. The prevalence of rapid fibrosers at 4 months, 1 and 2 years between patients with or without preservation injury was not statistically significant (p = 0.39, p = 0.46, and p = 0.53, respectively). No differences were seen between patients with and without PI in terms of patient and graft survival.

Conclusion

In this study, the presence and severity of preservation injury were not associated with development of rapid HCV recurrence or worsening in survival.

Keywords

Hepatic ischemia Reperfusion injury Liver transplant Hepatitis C Fibrosis 

Notes

Conflict of interest

None.

References

  1. 1.
    Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med. 2006;144:705–714.PubMedCrossRefGoogle Scholar
  2. 2.
    Wasley A, Alter MJ. Epidemiology of hepatitis C: geographic differences and temporal trends. Semin Liver Dis. 2000;20:1–16.PubMedCrossRefGoogle Scholar
  3. 3.
    Verna EC, Brown RS Jr. Hepatitis C and liver transplantation: enhancing outcomes and should patients be retransplanted. Clin Liver Dis. 2008;12:637–659.PubMedCrossRefGoogle Scholar
  4. 4.
    Charlton M, Seaberg E, Wiesner R, et al. Predictors of patient and graft survival following liver transplantation for hepatitis C. Hepatology. 1991;28:823–830.CrossRefGoogle Scholar
  5. 5.
    Gallegos-Orozco JF, Yosephy A, Noble B, et al. Natural history of post-liver transplantation hepatitis C: a review of factors that may influence its course. Liver Transpl. 2009;15:1872–1881.PubMedCrossRefGoogle Scholar
  6. 6.
    Ghobrial RM, Steadman R, Gornbein J, et al. A 10-year experience of liver transplantation for hepatitis C: analysis of factors determining outcome in over 500 patients. Ann Surg. 2001;234:384–393.PubMedCrossRefGoogle Scholar
  7. 7.
    Manez R, Mateo R, Tabasco J, Kusne S, Starzl TE, Duquesnoy RJ. The influence of HLA donor-recipient compatibility on the recurrence of HBV and HCV hepatitis after liver transplantation. Transplantation. 1995;59:640–642.PubMedGoogle Scholar
  8. 8.
    Manousou P, Samonakis D, Cholongitas E, et al. Outcome of recurrent hepatitis C virus after liver transplantation in a randomized trial of tacrolimus monotherapy versus triple therapy. Liver Transpl. 2009;15:1783–1791.PubMedCrossRefGoogle Scholar
  9. 9.
    Rosen HR, Chou S, Corless CL, et al. Cytomegalovirus viremia: risk factor for allograft cirrhosis after liver transplantation for hepatitis C. Transplantation. 1997;64:721–726.PubMedCrossRefGoogle Scholar
  10. 10.
    Velidedeoglu E, Mange KC, Frank A, et al. Factors differentially correlated with the outcome of liver transplantation in hcv+ and HCV− recipients. Transplantation. 2004;77:1834–1842.PubMedCrossRefGoogle Scholar
  11. 11.
    Watt KD, Lyden ER, Gulizia JM, McCashland TM. Recurrent hepatitis C posttransplant: early preservation injury may predict poor outcome. Liver Transpl. 2006;12:134–139.PubMedCrossRefGoogle Scholar
  12. 12.
    Lee YM, O’Brien CB, Yamashiki N, et al. Preservation injury patterns in liver transplantation associated with poor prognosis. Transplant Proc. 2003;35:2964–2966.PubMedCrossRefGoogle Scholar
  13. 13.
    Tillery W, Demetris J, Watkins D, et al. Pathologic recognition of preservation injury in hepatic allografts with six months follow-up. Transplant Proc. 1989;21:1330–1331.PubMedGoogle Scholar
  14. 14.
    Baron PW, Sindram D, Higdon D, et al. Prolonged rewarming time during allograft implantation predisposes to recurrent hepatitis C infection after liver transplantation. Liver Transpl. 2000;6:407–412.PubMedCrossRefGoogle Scholar
  15. 15.
    Camargo CA Jr, Madden JF, Gao W, Selvan RS, Clavien PA. Interleukin-6 protects liver against warm ischemia/reperfusion injury and promotes hepatocyte proliferation in the rodent. Hepatology. 1997;26:1513–1520.PubMedCrossRefGoogle Scholar
  16. 16.
    Selzner M, Camargo CA, Clavien PA. Ischemia impairs liver regeneration after major tissue loss in rodents: protective effects of interleukin-6. Hepatology. 1999;30:469–475.PubMedCrossRefGoogle Scholar
  17. 17.
    Brokelman W, Stel AL, Ploeg RJ. Risk factors for primary dysfunction after liver transplantation in the University of Wisconsin solution era. Transplant Proc. 1999;31:2087–2090.PubMedCrossRefGoogle Scholar
  18. 18.
    Busquets J, Figueras J, Serrano T, et al. Postreperfusion biopsies are useful in predicting complications after liver transplantation. Liver Transpl. 2001;7:432–435.PubMedCrossRefGoogle Scholar
  19. 19.
    Ploeg RJ, D’Alessandro AM, Knechtle SJ, et al. Risk factors for primary dysfunction after liver transplantation—a multivariate analysis. Transplantation. 1993;55:807–813.PubMedCrossRefGoogle Scholar
  20. 20.
    Firpi RJ, Abdelmalek MF, Soldevila-Pico C, et al. One-year protocol liver biopsy can stratify fibrosis progression in liver transplant recipients with recurrent hepatitis C infection. Liver Transpl. 1991;10:1240–1247.CrossRefGoogle Scholar
  21. 21.
    Ishak K, Baptista A, Bianchi L, et al. Histological grading and staging of chronic hepatitis. J Hepatol. 1991;22:696–699.CrossRefGoogle Scholar
  22. 22.
    Killackey MT, Gondolesi GE, Liu LU, et al. Effect of ischemia-reperfusion on the incidence of acute cellular rejection and timing of histologic hepatitis C virus recurrence after liver transplantation. Transplant Proc. 2008;40:1504–1510.PubMedCrossRefGoogle Scholar
  23. 23.
    Shackleton CR, Martin P, Melinek J, et al. Lack of correlation between the magnitude of preservation injury and the incidence of acute rejection, need for OKT3, and conversion to FK506 in cyclosporine-treated primary liver allograft recipients. Transplantation. 1995;60:554–558.PubMedCrossRefGoogle Scholar
  24. 24.
    Briceno J, Marchal T, Padillo J, Solorzano G, Pera C. Influence of marginal donors on liver preservation injury. Transplantation. 2002;74:522–526.PubMedCrossRefGoogle Scholar
  25. 25.
    Boker KH, Dalley G, Bahr MJ, et al. Long-term outcome of hepatitis C virus infection after liver transplantation. Hepatology. 1997;25:203–210.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  • Anthony J. Michaels
    • 3
  • Renumathy Dhanasekaran
    • 1
  • David P. Foley
    • 4
  • Ahmad Alkhasawneh
    • 2
  • Lisa Dixon
    • 2
  • Consuelo Soldevila-Pico
    • 1
  • Giuseppe Morelli
    • 1
  • Roniel Cabrera
    • 1
  • Virginia C. Clark
    • 1
  • Roberto J. Firpi
    • 1
  1. 1.Division of Gastroenterology, Hepatology and Nutrition Section of Hepatobiliary Diseases and Liver Transplantation, Department of MedicineUniversity of FloridaGainesvilleUSA
  2. 2.Department of PathologyUniversity of FloridaGainesvilleUSA
  3. 3.Division of Gastroenterology and HepatologyThe Ohio State University Medical CenterColumbusUSA
  4. 4.Department of SurgeryUniversity of Wisconsin School of Medicine and Public HealthMadisonUSA

Personalised recommendations